{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:26:54Z","timestamp":1788280014447,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clinthera.2022.06.002","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T07:47:17Z","timestamp":1656661637000},"page":"930-944.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetic Interactions Between Tegoprazan and Naproxen, Aceclofenac, and Celecoxib in Healthy Korean Male Subjects"],"prefix":"10.1016","volume":"44","author":[{"given":"Seol Ju","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naree","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MinJa","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongtae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7269-9533","authenticated-orcid":false,"given":"Min-Gul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.06.002_bib0001","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/187152312803476255","article-title":"Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review","volume":"11","author":"Bacchi","year":"2012","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0002","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3748\/wjg.v18.i18.2147","article-title":"Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility","volume":"18","author":"Takeuchi","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0003","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/JPR.S156938","article-title":"Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits","volume":"11","author":"Gwee","year":"2018","journal-title":"J Pain Res"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0004","article-title":"Gastro-oesophageal Reflux Disease and Dyspepsia in Adults: Investigation and Management","year":"2014","journal-title":"London: NICE;"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0005","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0006","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/jpet.117.244202","article-title":"Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility","volume":"364","author":"Takahashi","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0007","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/apt.15480","article-title":"Editorial: potassium-competitive acid blockers for acid-related diseases-tegoprazan, a new kid on the block","volume":"50","author":"Scarpignato","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0008","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/apt.15185","article-title":"Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis","volume":"49","author":"Lee","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0009","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"Shin","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0010","unstructured":"Usage of major NSAIDs with PPIs (2013-2018). Health Insurance Review & Assessment Service. Data analyzed by HK inno.N Corp., Seoul, Republic of Korea. Unpublished."},{"key":"10.1016\/j.clinthera.2022.06.002_bib0011","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2165\/00003088-199732040-00002","article-title":"Clinical pharmacokinetics of naproxen","volume":"32","author":"Davies","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0012","first-page":"597","article-title":"The effects of cimetidine, ranitidine and famotidine on the single-dose pharmacokinetics of naproxen and its metabolites in humans","volume":"31","author":"Vree","year":"1993","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0013","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0009-9236(03)00167-X","article-title":"Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac","volume":"74","author":"Hinz","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0014","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2165\/00003088-199733030-00003","article-title":"Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls","volume":"33","author":"Davies","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003088-200038030-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor","volume":"38","author":"Davies","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0016","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2165\/00003495-200059040-00017","article-title":"Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain","volume":"59","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0017","unstructured":"Tegoprazan Investigator's Brochure. Version 10. HK inno.N Corp. Republic of Korea. 31 December 2019."},{"key":"10.1016\/j.clinthera.2022.06.002_bib0018","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/pharmaceutics13091489","article-title":"Prediction of drug\u2013drug interaction potential of tegoprazan using physiologically based pharmacokinetic modeling and simulation","volume":"13","author":"Yoon","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0019","unstructured":"Ministry of Food and Drug Safety, Guideline on Bioanalytical Method Validation, 2013."},{"key":"10.1016\/j.clinthera.2022.06.002_bib0020","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/aps.2011.138","article-title":"Pharmacokinetics and safety of calcium L-threonate in healthy volunteers after single and multiple oral administrations","volume":"32","author":"Wang","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105812","article-title":"Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: an UNGAP review","volume":"162","author":"Vinarov","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0022","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jconrel.2009.01.027","article-title":"Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: amorphous naproxen-cimetidine mixtures prepared by mechanical activation","volume":"136","author":"Alleso","year":"2009","journal-title":"J Control Release"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0023","first-page":"11","article-title":"Formulation and characterization of aceclofenac-loaded nanofiber based orally dissolving webs","author":"Sipos","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0024","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/15701638113109990035","article-title":"Design and characterization of microcrystals for enhanced dissolution rate of celecoxib","volume":"10","author":"Lakshmi","year":"2013","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/00044011-200525110-00006","article-title":"Lack of pharmacokinetic interaction between esomeprazole and the nonsteroidal anti-inflammatory drugs naproxen and rofecoxib in healthy subjects","volume":"25","author":"Hassan-Alin","year":"2005","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0026","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s002280050482","article-title":"Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole","volume":"54","author":"Andersson","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0027","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4196\/kjpp.2018.22.3.321","article-title":"Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans","volume":"22","author":"Bae","year":"2018","journal-title":"Korean J Physiol Pharmacol"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0028","doi-asserted-by":"crossref","first-page":"31","DOI":"10.14227\/DT150208P31","article-title":"Development of discriminating method for dissolution of aceclofenac marketed formulations","volume":"15","author":"Soni","year":"2008","journal-title":"Dissolution technologies"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0029","doi-asserted-by":"crossref","first-page":"20325","DOI":"10.3390\/molecules191220325","article-title":"Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process","volume":"19","author":"Ha","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0030","first-page":"2325","article-title":"Solubility enhancement of poorly water soluble celecoxib for parenteral formualtions","volume":"3","author":"Agrawal","year":"2012","journal-title":"Int J Pharm Sci Res"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0031","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/rheumatology\/keh627","article-title":"Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors","volume":"44","author":"Huntjens","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0032","first-page":"728","article-title":"Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0033","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.108.191087","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"118","author":"Bhatt","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0034","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guidelines for the management of rheumatoid arthritis: 2002 Update","volume":"46","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2022.06.002_bib0035","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.mayocp.2014.07.015","article-title":"Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine","volume":"89","author":"Marlicz","year":"2014","journal-title":"Mayo Clin Proc"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:10Z","timestamp":1758963430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822002144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0149291822002144"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.06.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic Interactions Between Tegoprazan and Naproxen, Aceclofenac, and Celecoxib in Healthy Korean Male Subjects","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}